CN103041118B - 一种具有降血糖降血脂作用的组合物 - Google Patents
一种具有降血糖降血脂作用的组合物 Download PDFInfo
- Publication number
- CN103041118B CN103041118B CN201310030989.6A CN201310030989A CN103041118B CN 103041118 B CN103041118 B CN 103041118B CN 201310030989 A CN201310030989 A CN 201310030989A CN 103041118 B CN103041118 B CN 103041118B
- Authority
- CN
- China
- Prior art keywords
- extract
- blood
- hyperlipidemia
- composition
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000002218 hypoglycaemic effect Effects 0.000 title description 14
- 230000000055 hyoplipidemic effect Effects 0.000 title 1
- 239000008280 blood Substances 0.000 claims abstract description 69
- 210000004369 blood Anatomy 0.000 claims abstract description 69
- 239000000284 extract Substances 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 33
- 230000001603 reducing effect Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 3
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012567 medical material Substances 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 52
- 240000000249 Morus alba Species 0.000 abstract description 42
- 235000008708 Morus alba Nutrition 0.000 abstract description 42
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 35
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 35
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 34
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 34
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 32
- 235000009811 Momordica charantia Nutrition 0.000 abstract description 22
- 150000002632 lipids Chemical class 0.000 abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 244000269722 Thea sinensis Species 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 230000003914 insulin secretion Effects 0.000 abstract description 3
- 241000304531 Allium macrostemon Species 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004089 microcirculation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 23
- 244000302512 Momordica charantia Species 0.000 description 21
- 201000001421 hyperglycemia Diseases 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 11
- 244000291564 Allium cepa Species 0.000 description 10
- 229930013930 alkaloid Natural products 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 241000234282 Allium Species 0.000 description 7
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 3
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 3
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- -1 Lipid peroxide Chemical class 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000009815 Momordica Nutrition 0.000 description 2
- 241000218984 Momordica Species 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003138 coordinated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310030989.6A CN103041118B (zh) | 2013-01-28 | 2013-01-28 | 一种具有降血糖降血脂作用的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310030989.6A CN103041118B (zh) | 2013-01-28 | 2013-01-28 | 一种具有降血糖降血脂作用的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103041118A CN103041118A (zh) | 2013-04-17 |
CN103041118B true CN103041118B (zh) | 2014-10-01 |
Family
ID=48054129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310030989.6A Expired - Fee Related CN103041118B (zh) | 2013-01-28 | 2013-01-28 | 一种具有降血糖降血脂作用的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103041118B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491339A (zh) * | 2014-12-30 | 2015-04-08 | 北京宝得瑞食品有限公司 | 一种防治高脂血症及抗血栓的沙棘叶组合物及制备方法 |
CN104720064A (zh) * | 2015-04-14 | 2015-06-24 | 河南爱因糖尿病健康科学研究院股份有限公司 | 一种苦瓜桑叶饮品及其制备方法 |
CN104873893A (zh) * | 2015-05-23 | 2015-09-02 | 周末 | 一种降血脂的药物组合物 |
CN105146338A (zh) * | 2015-08-03 | 2015-12-16 | 重庆赛福食品有限公司 | 一种减肥降糖麦片及其制备方法 |
CN105726655A (zh) * | 2016-02-22 | 2016-07-06 | 天津农学院 | 一种辅助降血脂功效组合物及其应用 |
CN107308215A (zh) * | 2017-05-11 | 2017-11-03 | 浙江省农业科学院 | 一种植物源性降糖降脂药物 |
CN107232539A (zh) * | 2017-05-13 | 2017-10-10 | 宁远平 | 苦薤见肿消及其制作方法 |
CN112216394B (zh) * | 2019-07-11 | 2024-11-15 | 浙江远图技术股份有限公司 | 一种基于自适应寻优模型的血糖变化趋势预测系统 |
CN110558568A (zh) * | 2019-10-25 | 2019-12-13 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种降三高营养组合的功能食品及其制备方法 |
CN112138095A (zh) * | 2020-09-30 | 2020-12-29 | 大连元固康健科技有限公司 | 可有效提高降血糖功效的组合物及用途 |
CN113796537B (zh) * | 2021-09-22 | 2023-08-22 | 尚品生物科技(天津)有限公司 | 一种降糖组合物及其制作工艺 |
CN116036136B (zh) * | 2022-06-29 | 2024-12-31 | 上海理工大学 | 一种缓解糖尿病、前驱糖尿病的益生菌制品、制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726992A (zh) * | 2005-06-24 | 2006-02-01 | 焦家良 | 一种调节血糖及血脂含量的中药及其制备方法 |
CN101433689A (zh) * | 2008-12-15 | 2009-05-20 | 汝州市中医院 | 葛根薤白口服液及制备方法 |
-
2013
- 2013-01-28 CN CN201310030989.6A patent/CN103041118B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1726992A (zh) * | 2005-06-24 | 2006-02-01 | 焦家良 | 一种调节血糖及血脂含量的中药及其制备方法 |
CN101433689A (zh) * | 2008-12-15 | 2009-05-20 | 汝州市中医院 | 葛根薤白口服液及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103041118A (zh) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
CN101239112A (zh) | 调节血脂的中药组合物及其制备方法 | |
JP5969590B2 (ja) | 血糖、脂血及び体重を抑制する薬物組成物 | |
CN101085079B (zh) | 一种用于治疗糖尿病的中药复方及其制备方法和应用 | |
CN101518595A (zh) | 具有降脂减肥、抗氧化功能的药物组合物及其制备方法 | |
CN101804110B (zh) | 一种抗血栓和降血脂的中药制剂 | |
CN101011562A (zh) | 参芪温胆汤新剂型及其生产方法 | |
CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
RU2442598C1 (ru) | Мочегонное средство | |
CN104306554A (zh) | 一种治疗胃溃疡的食品、保健品或药物组合物 | |
CN102631482B (zh) | 一种具有防治糖尿病及并发症的中药组合物 | |
CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
KR100514132B1 (ko) | 체중 감소용 생약 조성물 및 이를 포함하는 체중 감소용 키트 | |
CN103893613A (zh) | 一种治疗口腔溃疡的药物及制备方法 | |
CN103385931A (zh) | 一种降血糖的药物组合物 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
CN104606571A (zh) | 一种生津止渴鲜菠菜根代茶饮及制备方法 | |
CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
CN114767794B (zh) | 一种治疗动脉斑块的中药 | |
CN105169187B (zh) | 一种组合物及其应用,其制备方法以及含有该组合物的药物、食品 | |
CN103798472A (zh) | 一种保健茶及保健养生制剂 | |
CN104225185B (zh) | 一种降血糖口香糖及其生产方法 | |
CN113577137B (zh) | 一种治疗痤疮的中药组合物及其制备方法与应用 | |
KR101934811B1 (ko) | 복합 생약 추출물을 포함하는 혈행 개선용 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE Free format text: FORMER OWNER: ZHAO QUANCHENG Effective date: 20140813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Chenggang Inventor after: Wang Xiaoli Inventor after: Chang Jiayi Inventor after: Zhang Xian Inventor after: Zhao Quancheng Inventor after: He Yufang Inventor before: Zhao Quancheng Inventor before: Nan Minlun Inventor before: He Yufang Inventor before: Ma Jisheng Inventor before: Chang Yanru Inventor before: Zhao Yuwei Inventor before: Wang Lianping |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130012 CHANGCHUN, JILIN PROVINCE TO: 150041 HARBIN, HEILONGJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHAO QUANCHENG NAN MINLUN HE YUFANG MA JISHENG CHANG YANRU ZHAO YUWEI WANG LIANPING TO: LIU CHENGGANG WANG XIAOLI CHANG JIAYI ZHANG XIAN ZHAO QUANCHENG HE YUFANG |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140813 Address after: 150041 Heping Road 24, Xiangfang District, Heilongjiang, Harbin Applicant after: Heilongjiang University of Chinese Medicine Address before: 130012 Changchun high tech Zone, Jilin pioneering Street No. 155 Applicant before: Zhao Quancheng |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141001 Termination date: 20180128 |
|
CF01 | Termination of patent right due to non-payment of annual fee |